Literature DB >> 32968876

Colorectal cancer under 20 years old: a retrospective analysis from three tertiary hospitals.

Weiwei Xiao1, Xiaohao Wang1, Chengjing Zhou1, Haiyang Chen2, Shaoqing Niu3, Qiaoxuan Wang1, Hui Chang1, Xiaojun Wu4, Peirong Ding4, Zhizhong Pan4, Xiangbo Wan2, Yong Bao3, Yuanhong Gao5.   

Abstract

PURPOSE: Colorectal cancer (CRC) rarely occurs in children and adolescents. This study aimed to perform a retrospective analysis and disclose more detailed information about CRC in patients under 20 years old.
METHODS: Medical records of CRCs in patients under 20 years old referred to three tertiary hospitals in China from September 2000 to July 2019 were retrospectively reviewed. Clinicopathological characteristics, treatment processes and laboratory findings were summarized and treatment outcomes and prognostic factors were analyzed.
RESULTS: A total of 33,394 CRC medical records were analyzed, and we identified seventy (0.21%) CRCs in patients under 20. The most common primary tumor location was the left hemicolon (35.7%). The prominent pathological types were mucinous adenocarcinoma (22.9%) and signet ring cell carcinoma (22.9%). Nearly half (47.1%) of the patients presented with distant metastasis at diagnosis. The fractions of patients with deficient mismatch repair (dMMR) protein expression and microsatellite instability-high (MSI-H) were 23.8% (5/21) and 71.4% (5/7), respectively. Forty-four patients underwent radical surgery. Fifty-five patients received chemotherapy and six patients received radiotherapy. One dMMR/MSI-H rectal cancer patient received immunotherapy and achieved a clinically complete response. The median overall survival (OS) time was 80 months. The 3-year and 5-year OS rates were 61.8% and 57.2%, respectively. An absence of distant metastasis was a favorable factor for OS. For stage II/III CRCs, classic adenocarcinoma and radical surgery were favorable factors for OS. For stage IV CRCs, primary location at the colon was a favorable factor for OS.
CONCLUSION: Child and adolescent CRC patients are likely to have distant metastasis, undifferentiated, left hemicolon location, and a dMMR/MSI-H phenotype at diagnosis. Additional efforts are needed to improve their survival outcomes.

Entities:  

Keywords:  Colorectal cancer; DNA mismatch repair; Pediatric cancer; Therapy

Mesh:

Substances:

Year:  2020        PMID: 32968876      PMCID: PMC7954766          DOI: 10.1007/s00432-020-03397-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  26 in total

1.  Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base.

Authors:  John R Hyngstrom; Chung-Yuan Hu; Yan Xing; Y Nancy You; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas; Janice N Cormier; George J Chang
Journal:  Ann Surg Oncol       Date:  2012-04-04       Impact factor: 5.344

Review 2.  Signet-ring cell carcinoma of colorectum--current perspectives and molecular biology.

Authors:  Vinod Gopalan; Robert Anthony Smith; Yik-Hong Ho; Alfred King-Yin Lam
Journal:  Int J Colorectal Dis       Date:  2010-08-05       Impact factor: 2.571

3.  Carcinoma of the colon in children: a report of six new cases and a review of the literature.

Authors:  A Andersson; L Bergdahl
Journal:  J Pediatr Surg       Date:  1976-12       Impact factor: 2.545

4.  Adolescent and young adult oncology-past, present, and future.

Authors:  Allison G Close; Alexandra Dreyzin; Kimberly D Miller; Brittani K N Seynnaeve; Louis B Rapkin
Journal:  CA Cancer J Clin       Date:  2019-10-08       Impact factor: 508.702

5.  Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study.

Authors:  Muhammet Ali Kaplan; Sukru Ozaydin; Halis Yerlikaya; Mustafa Karaagac; Mahmut Gumus; Timucin Cil; Ülkü Yalcintas Arslan; Nuriye Ozdemir; Abdullah Sakin; Mehmet Bilici; Dogan Koca; Mukremin Uysal; Faysal Dane; Özlem Nuray Sever; Mehmet Metin Seker; Zeynep Oruc Seker; Mehmet Fatih Can; Caglayan Geredeli; Asude Aksoy; Keziban Nur Pilanci; Turkan Ozturk Topcu; Abdurrahman Isikdogan
Journal:  Oncol Res Treat       Date:  2019-08-22       Impact factor: 2.825

Review 6.  Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

Authors:  E Auclin; A Zaanan; D Vernerey; R Douard; C Gallois; P Laurent-Puig; F Bonnetain; J Taieb
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

Review 7.  The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment.

Authors:  Louise C Connell; José Mauricio Mota; Maria Ignez Braghiroli; Paulo M Hoff
Journal:  Curr Treat Options Oncol       Date:  2017-04

8.  Colorectal carcinoma in childhood and adolescence: a clinicopathologic review.

Authors:  D Ashley Hill; Wayne L Furman; Catherine A Billups; Shannon E Riedley; Alvida M Cain; Bhaskar N Rao; Charles B Pratt; Sheri L Spunt
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Authors:  Lorenzo F Fanchi; Krijn K Dijkstra; José G Van den Berg; Emile E Voest; John B Haanen; Myriam Chalabi; Arend G Aalbers; Karolina Sikorska; Marta Lopez-Yurda; Cecile Grootscholten; Geerard L Beets; Petur Snaebjornsson; Monique Maas; Marjolijn Mertz; Vivien Veninga; Gergana Bounova; Annegien Broeks; Regina G Beets-Tan; Thomas R de Wijkerslooth; Anja U van Lent; Hendrik A Marsman; Elvira Nuijten; Niels F Kok; Maria Kuiper; Wieke H Verbeek; Marleen Kok; Monique E Van Leerdam; Ton N Schumacher
Journal:  Nat Med       Date:  2020-04-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.